Trimethylamine N-Oxide Induces Renal Fibrosis Through the PI3K/AKT/SREBP1 Pathway

CHEN Jing, HUANG Yinghui, ZHAO Jinghong

Abstract

To investigate the role and mechanism of trimethylamine N-oxide (TMAO), a uremic toxin, in renal fibrosis.   Methods  A total of 20 male BALB/c mice were randomly and evenly assigned to a Control group and a TMAO group. Mice in the Control group received intraperitoneal injection of normal saline, while mice in the TMAO group received intraperitoneal injection of TMAO (20 mg/[kg·d]). The injection was given once a day for 8 weeks. Histopathology and fibrosis of kidney were observed by H&E staining and Masson staining. Immunohistochemistry was performed to determine the levels of alpha smooth muscle actin (α-SMA), recombinant human fibronectin fragment (Fibronectin), and sterol-regulatory element binding protein 1 (SREBP1). Western blot was performed to determine α-SMA, SREBP1, phosphatidylinositol 3 kinase (PI3K), phospho-phosphatidylinositol 3 kinase (p-PI3K), protein kinase B (PKB, also known as AKT), and phospho-AKT (p-AKT) protein levels. HK2 cells were treated with SREBP1 small interfering RNA (siRNA) and PI3K/AKT inhibitor, respectively, and the reversal of the effects of TMAO was examined.   Results  Animal experiments showed that, compared with the Control group, the mice treated with TMAO experienced pathological damage and fibrosis of the kidney tissue and the expression levels of fibrosis markers, α-SMA and Fibronectin, in the kidney were increased (all P<0.05). According to the findings from further investigation, the TMAO-treatment group showed increased expression of SREBP1 and an up-regulation of PI3K phosphorylation ratio and AKT phosphorylation ratio compared with those of the Control group (all P<0.05). Cell experiments produced results similar to those of the animal experiment. After siRNA interference with SREBP1 expression, the expression levels of fibrosis marker proteins decreased (P<0.05). Besides, the high expression of SREBP1 caused by TMAO was inhibited after HK2 cells were incubated with LY294002, a PI3K-AKT pathway inhibitor (P<0.05).   Conclusion  TMAO may induce renal fibrosis by promoting the PI3K/AKT/SREBP1 pathway.

 

Keywords: Trimethylamine N-oxide,  Renal fibrosis,  PI3K/AKT pathway,  SREBP1

 

Full Text:

PDF


References


HUMPHREYS B D. Mechanisms of renal fibrosis. Annu Rev Physiol， 2018，80(1): 309–326. doi: 10.1146/annurev-physiol-022516-034227.

RUIZ-ORTEGA M， LAMAS S， ORTIZ A. Antifibrotic agents for the management of CKD: a review. Am J Kidney Dis，2022，80(2): 251–263. doi: 10.1053/j.ajkd.2021.11.010.

ZHOU W， WU W H， SI Z L， et al. The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice. Nat Commun，2022，13(1): 6081. doi: 10.1038/s41467-022-33824-6.

CHEN J， TANG Y， ZHONG Y， et al. P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition. Mol Ther ISSN，2022，30(9): 3017–3033. doi: 10.1016/j.ymthe. 2022.06.019.

GENG X Q， MA A， HE J Z， et al. Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways. Acta Pharmacol Sin，2020，41(5): 670–677. doi: 10.1038/s41401-019-0324-7.

LI S， QIU B， LU H， et al. Hyperhomocysteinemia accelerates acute kidney injury to chronic kidney disease progression by downregulating heme oxygenase-1 expression. Antioxid Redox Signal，2019，30(13): 1635–1650. doi: 10.1089/ars.2017.7397.

NAKANO T， WATANABE H， IMAFUKU T， et al. Indoxyl sulfate contributes to mTORC1-induced renal fibrosis via the OAT/NADPH oxidase/ROS pathway. Toxins，2021，13(12): 909. doi: 10.3390/toxins13120909.

SUN B， WANG X， LIU X， et al. Hippuric acid promotes renal fibrosis by disrupting redox homeostasis via facilitation of NRF2-KEAP1-CUL3 interactions in chronic kidney disease. Antioxidants，2020，9(9): 783. doi: 10.3390/antiox9090783.

WANG S， ZUO A， JIANG W， et al. JMJD1A/NR4A1 signaling regulates the procession of renal tubular epithelial interstitial fibrosis induced by AGEs in HK-2. Front Med，2021，8: 807694. doi: 10.3389/fmed.2021. 807694.

RAYEGO-MATEOS S， VALDIVIELSO J M. New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opin Ther Targets，2020，24(7): 655–670. doi: 10.1080/14728222.2020.1762173.

WU K， YUAN Y， YU H， et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood，2020，136(4): 501–515. doi: 10.1182/blood. 2019003990.

KIM S J， ZHANG X， CHO S B， et al. Uremic solutes of indoxyl sulfate and p-cresol enhance protease-activated receptor-2 expression in vitro and in vivo in keratinocytes. Hum Exp Toxicol，2021，40(1): 113–123. doi: 10.1177/0960327120945758.

JIANG S， SHUI Y， CUI Y， et al. Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin Ⅱ-induced hypertension. Redox Biol，2021，46: 102115. doi: 10.1016/j.redox.2021.102115.

CHU H， DU C， YANG Y， et al. MC-LR aggravates liver lipid metabolism disorders in obese mice fed a high-fat diet via PI3K/AKT/mTOR/SREBP1 signaling pathway. Toxins，2022，14(12): 833. doi: 10.3390/toxins14120833.

ZHOU Z， LIANG S， ZHOU Z， et al. TGF-β1 promotes SCD1 expression via the PI3K-Akt-mTOR-SREBP1 signaling pathway in lung fibroblasts. Respir，2023，24(1): 8. doi: 10.1186/s12931-023-02313-9.

SHI H H， CHEN L P， WANG C C， et al. Docosahexaenoic acid-acylated curcumin diester alleviates cisplatin-induced acute kidney injury by regulating the effect of gut microbiota on the lipopolysaccharide- and trimethylamine-N-oxide-mediated PI3K/Akt/NF-κB signaling pathway in mice. Food Funct，2022，13(11): 6103–6117. doi: 10.1039/d1fo04178a.

LI D， KE Y， ZHAN R， et al. Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice. Aging Cell，2018，17(4): e12768. doi: 10.1111/acel.12768.

ZENG Y， GUO M， FANG X， et al. Gut microbiota-derived trimethylamine N-oxide and kidney function: a systematic review and meta-analysis. Adv Nutr，2021，12(4): 1286–1304. doi: 10.1093/advances/ nmab010.

FANG Q， ZHENG B， LIU N， et al. Trimethylamine N-oxide exacerbates renal inflammation and fibrosis in rats with diabetic kidney disease. Front Physiol，2021，12: 682482. doi: 10.3389/fphys.2021.682482.


Refbacks

  • There are currently no refbacks.